(IN BRIEF) Almirall, a leading biopharmaceutical company specializing in medical dermatology, has reported its full-year 2023 financial results, showcasing a…
(IN BRIEF) Almirall S.A., a leading pharmaceutical company specializing in medical dermatology, has finalized an exclusive license agreement with Novo…
(IN BRIEF) Almirall S.A., a global pharmaceutical company specializing in medical dermatology, has confirmed its involvement in the 42nd Annual…
(IN BRIEF) EpimAb Biotherapeutics, a clinical-stage biopharmaceutical company specializing in multispecific antibodies, and Almirall, a global biopharmaceutical company focused on…
(IN BRIEF) Almirall, a global biopharmaceutical company specializing in medical dermatology, has entered into an agreement with Centrient Pharmaceuticals, a…
Durch diese Lizenzvereinbarung mit Ablexis erhält Almirall Rechte zur Nutzung der AlivaMab®-Maustechnologie für die Forschung, Entwicklung und Vermarktung von Antikörpern…
Through this license agreement with Ablexis, Almirall is granted rights to use the AlivaMab® Mouse technology for research, development, and…
These collaborations are in response to the calls for innovation via AlmirallShare, the open innovation platform of Almirall and aim…
Most of the 64 million COPD patients around the world, including over 2 million in Spain, must contend with breathlessness,…
Barcelona, 05-8-2013 — /EuropaWire/ — Almirall’s H1: Executing on growth platforms, financial delivery on track Financial performance in line with guidance…